Question explored with the scientific record
Conversation so far
- 1 which receptors are likely hit too hard by this combo of meds taken near bedtime: clonazapam .5mg, mirtazapine 30mg, gabapentin 600mg, olanzapine 7.5mg
- 2 what effect do they have on weight both with and without terzepatide 7.5mg
- 3 I forgot to mention belsomra. Its use is intended to allow good sleep while reducing the GABA agonist meds.
Answered on this page ↓
I forgot to mention belsomra. Its use is intended to allow good sleep while reducing the GABA agonist meds.
The short version: Belsomra (suvorexant) improves sleep but carries a clear risk of next-day sedation, rebound insomnia on stopping, and a strong link to nightmares and abnormal dreams.
The evidence on Belsomra comes from manufacturer-funded trials and independent meta-analyses. A 2015 systematic review of four placebo-controlled trials (3,076 adults) found it improved subjective total sleep time by about 20 minutes and reduced time to fall asleep by about 8 minutes at one month [2]. A 2020 model-based meta-analysis of 43 trials ranked suvorexant as the best drug for reducing wake-after-sleep-onset, though it noted that placebo response accounted for about 60% of the measured effect [4].
The safety picture matters more. The same 2015 review found suvorexant tripled the risk of somnolence (RR 3.16) and doubled the risk of fatigue (RR 2.09) [2]. Rebound insomnia was real: about 1 in 11 people had worse sleep on stopping [2]. A 2025 network meta-analysis of 102 trials confirmed suvorexant's somnolence risk (RR 3.32) [5]. A 2026 analysis of real-world FAERS reports in older adults found suvorexant had strong signals for nightmares (ROR 85.91) and abnormal dreams [6].
| Outcome | Suvorexant vs placebo | Evidence |
|---|---|---|
| Sleep time improvement | +20 min at 1 month | [2] |
| Somnolence risk | 3.3x higher | [5] |
| Fatigue risk | 2.1x higher | [2] |
| Rebound insomnia | 1 in 11 affected | [2] |
| Nightmare signal | Strong (ROR 85.91) | [6] |
The retrieved evidence does not include a study testing suvorexant specifically with clonazepam, mirtazapine, gabapentin, or olanzapine. No trial examined weight change with suvorexant. The 2025 rat study found no change in litter weight gain, but that is a different species and context [1]. The question of whether suvorexant allows reducing GABA agonist doses is plausible on mechanism—it works through orexin antagonism, not GABA—but no retrieved trial tested that switch directly [3].
My call: suvorexant improves sleep but carries real risks of daytime sedation, rebound insomnia, and disturbing dreams. The evidence does not answer whether it helps reduce other sleep medications or affects weight. Confidence: moderate for the sleep and safety data; low for the specific combination and weight questions.
Sources used 6
-
Dual hypocretin receptor antagonism enhances sleep and nursing behavior in lactating rats
Systemic blockade of hypocretin receptors with suvorexant promotes sleep in lactating and virgin female rats, with stronger hypnotic effects in virgins, while in lactating dams it simultaneously enhances nursing and milk ejections but reduces certain active maternal behaviors, w…
DOI: 10.1101/2025.09.05.674514 -
Suvorexant for Primary Insomnia: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials
A PRISMA-guided systematic review and meta-analysis of four randomized, placebo-controlled trials demonstrating that suvorexant improves key subjective sleep measures in adults with primary insomnia, with higher rates of some adverse events but similar discontinuation rates comp…
DOI: 10.1371/journal.pone.0136910 -
Orexin receptor antagonists in the treatment of insomnia associated with psychiatric disorders: a systematic review
This systematic review evaluates the clinical evidence for dual orexin receptor antagonists (suvorexant and lemborexant) in treating insomnia when it co-occurs with psychiatric disorders, synthesizing randomized trials and observational studies, assessing safety, potential benef…
DOI: 10.1038/s41398-024-03087-4 -
Pharmacological interventions for the treatment of insomnia: quantitative comparison of drug efficacy
Using a model-based meta-analysis of 43 randomized placebo-controlled trials (14,535 adults) across 11 FDA-approved insomnia drugs, the study quantifies time-course drug effects on sleep latency, wake after sleep onset, and total sleep time, finding eszopiclone most effective fo…
DOI: 10.1016/j.sleep.2020.03.022 -
Adverse events of pharmacological interventions for insomnia disorder in adults: a systematic review and network meta-analysis
In 102 RCTs (35,700 adults with primary insomnia), a network meta-analysis found most insomnia drugs increased risks of somnolence, dizziness, headache, dysgeusia, dry mouth, or nausea/vomiting versus placebo, none increased serious AEs, and doxepin lowered headache and somnolen…
DOI: 10.3389/fpsyt.2025.1461166 -
Comparative pharmacovigilance of non-benzodiazepine receptor agonists versus dual orexin receptor antagonists for insomnia in older adults
In FAERS reports for adults aged ≥65 years, nBZRAs showed strong signals for therapeutic failure and dysgeusia, whereas DORAs showed strong signals for nightmares, abnormal dreams, and hallucinations; neither class produced a significant fall signal.
DOI: 10.3389/fphar.2026.1788736